VERU INC. (The Female Health Company) - 10-Q Summary
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for The Female Health Company (VERU Inc.) for the period ended March 31, 2009. The Company manufactures, markets, and distributes the FC1 and FC2 female condoms, the only FDA-approved products under a woman's control for preventing unintended pregnancy and sexually transmitted infections (STIs), including HIV/AIDS. FC2 received FDA approval on March 10, 2009, enabling U.S. commercial launch and procurement by USAID.
Key Financial Metrics
| Metric | Three Months Ended Mar 31, 2009 | Six Months Ended Mar 31, 2009 |
|---|---|---|
| Net Revenues | $7,319,509 | $12,664,347 |
| Gross Profit | $3,892,935 (53% margin) | $6,334,129 (50% margin) |
| Operating Income | $2,250,481 | $2,689,417 |
| Net Income | $1,974,566 | $3,607,957 |
| Net Income Attributable to Common Stockholders | $1,951,786 | $3,560,602 |
| Diluted EPS | $0.07 | $0.13 |
| Cash and Restricted Cash | $1,748,973 (Total) | $1,748,973 (Total) |
| Working Capital | $8,603,803 | $8,603,803 |
| Stockholders' Equity | $9,602,521 | $9,602,521 |
Cash Flow (Six Months): Net cash provided by operating activities was $3,276,029. Net cash used in investing activities was $(507,736), primarily for capital expenditures. Net cash used in financing activities was $(2,603,920), driven by stock repurchases of $2,575,411.
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 14% ($918k) for the quarter and 4% ($528k) for the six months compared to the prior year periods. This was driven by a 21% (quarter) and 16% (six months) increase in unit volume, partially offset by a higher mix of lower-priced FC2 units.
- Margin Expansion: Gross profit margins improved significantly to 53% (quarter) and 50% (six months) from 42% in the prior year periods. This was due to higher unit volumes and a favorable shift toward the lower-cost FC2 product mix.
- Profitability: Operating income surged 172% for the quarter and 73% for the six months. Net income attributable to common stockholders increased 67% for the quarter and 80% for the six months.
- Foreign Currency: The weakening of the British pound against the U.S. dollar resulted in a foreign currency transaction loss of $194,286 for the quarter, compared to a loss of $5,053 in the prior year. However, for the six-month period, the exchange rate fluctuations resulted in a net gain of $999,820.
- Expense Management: Operating expenses decreased for the quarter but increased slightly for the six months due to higher compensation costs and Sarbanes-Oxley consulting fees, though these were offset by reduced R&D costs (no longer incurring one-time PMA submission costs).
Guidance, Outlook, and Risks
- Manufacturing Expansion: The Company announced a 150% expansion of FC2 manufacturing capacity in Malaysia, increasing annual capacity from 30 million to 75-80 million units. The project, costing approximately $900,000, is expected to be completed in the fourth quarter of fiscal 2009 and will be self-funded.
- Commercial Outlook: With FDA approval secured, FC2 is expected to be available in the U.S. in late summer 2009. The Company is seeking a commercial partner for U.S. distribution.
- Liquidity: The Company maintains a strong cash position with $1.55 million in cash and $202k in restricted cash. It has a $1.5 million revolving credit facility with Heartland Bank, though no amounts were outstanding as of March 31, 2009.
- Risks: Key risks include reliance on a single product line, dependence on public sector funding and government programs for HIV/AIDS prevention, foreign currency exchange fluctuations, and the ability to secure adequate capital for future growth. The Company also faces competition from male condoms and potential future female condom competitors.
Investor Verification Checklist
- FC2 U.S. Launch: Verify the timeline and commercial partner selection for the U.S. launch of FC2 expected in late summer 2009.
- Manufacturing Expansion Funding: Confirm the Company's ability to self-fund the $900,000 Malaysia expansion without diluting shareholders or incurring significant debt.
- Public Sector Orders: Monitor the status of large public sector orders, particularly from NACO (India) and USAID, which drive volume.
- Currency Hedging: Assess management's strategy for managing foreign currency risk given the significant impact of GBP/USD and MYR/USD fluctuations on earnings.
- Stock Repurchase Program: Track the remaining capacity of the stock repurchase program (1,400,500 shares remaining as of March 31, 2009) and its impact on share count and EPS.